Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms
“It’s never been more clear that we are delivering exactly what millions of people have been waiting for,” said HIMS CEO Andrew Dudum after Q2 results Hims. With analysts ranging from “Sell” to “Buy”, and social media buzzing, Hims & Hers remains one of 2025’s most talked-about healthcare stocks – its fortunes tightly tied to both the telehealth boom and…
